Evaluation of 1-year follow-up results of macular telangiectasia type 2 cases by optical coherence tomography angiography

Abstract

The results of 1-year follow-up with optical coherence tomography angiography (OCTA) of 3 patients with macular telangiectasia type 2 (MacTel 2) were evaluated. The 3X3 mm OCTA imaging was performed in January 2017 and February 2018. The superficial and deep capillary plexus vascular density changes of the whole area, the parafoveal temporal and parafoveal nasal areas were examined. The mean whole, parafoveal temporal, and parafoveal nasal vessel densities at superficial capillary plexus were 51.31, 50.39, 54.57 at baseline and 49.93, 46.79, 51.83 at 1-year follow-up, respectively. The mean whole, parafoveal temporal and parafoveal nasal vessel densities at deep capillary plexus were 59.06, 59.05, 63.39 at baseline and 52.18, 54.68, 57.9 at 1-year follow-up, respectively. In this case series, it was shown quantitatively that vessel densities of MacTel2 patients markedly decreased over time, more pronounced in the deep capillary plexus.

Keywords: vessel densities, superficial capillary plexus, deep capillary plexus

Introduction

Macular telangiectasia type 2 (MacTel2) is a bilateral retinal disease with characteristic alterations of the macular capillary network and neurosensory atrophy. It primarily affects the juxtafoveal region of the macula [1]. Optical coherence tomography angiography (OCTA) is a non-invasive imaging method for visualization of the retinal capillary network [2]. In recent years, OCTA has been examined as potential imaging modality to facilitate the diagnosis and characterization of MacTel2 [3]. In this case series, we aimed to evaluate the 1-year follow-up results of MacTel2 patients by OCTA.

Case descriptions

The MacTel2 patients who were followed in our clinic and diagnosed by fundus examination, fluorescein angiography (FA), and optical coherence tomography (OCT) were evaluated. The age and best-corrected visual acuity (VA) according to the Snellen chart of the patients were recorded. The eyes were divided into two groups as proliferative and non-proliferative MacTel2 [4].

Case 1

A 51-year-old female presented with VA of 0.3 in the right eye (OD) and 0.05 in the left eye (OS). The non-proliferative MacTel2 was present in both eyes (OU) and was followed for 2 years. The VA of OU was stable for 1 year and no treatment was performed. The OCTA images of OD and image features are shown at baseline and 1-year follow-up (Figure 1a,b).
Table 1: Vessel densities (%) of superficial and deep capillary plexus of the cases in en face OCTA are shown at baseline (upper) and 1-year follow-up (bottom).

|                | Superficial | Deep |
|----------------|-------------|------|
|                | Whole       | Parafoveal temporal | Parafoveal nasal | Whole       | Parafoveal temporal | Parafoveal nasal |
| Case 1 right   | 53.92       | 56.35             | 57.70             | 59.5        | 64.2               | 63.4             |
|                | 49.6        | 51.1              | 56.1              | 56.5        | 62.5               | 60.1             |
| Case 1 left    | 47.67       | 44.78             | 47.5              | 54.3        | 48.8               | 61.2             |
|                | 50.1        | 42.8              | 49.3              | 53.3        | 48.6               | 59.5             |
| Case 2 right   | 49.05       | 53.7              | 53.9              | 59.37       | 64.58              | 63.97            |
|                | 47.6        | 53.3              | 53.2              | 49.1        | 55.8               | 56.6             |
| Case 2 left    | 52.3        | 45.8              | 51.9              | 61.51       | 49.5               | 65.44            |
|                | 50.6        | 44.9              | 50.4              | 48.1        | 49.5               | 55.2             |
| Case 3 right   | 53.75       | 55.34             | 59.2              | 58.72       | 59.01              | 61.89            |
|                | 51.4        | 46.5              | 48.6              | 51.7        | 55.5               | 56.3             |
| Case 3 left    | 51.22       | 46.4              | 57.22             | 61.01       | 57.9               | 64.46            |
|                | 50.3        | 42.1              | 53.5              | 54.4        | 56.1               | 59.8             

Figure 1: Horizontal B-scan optical coherence tomography angiography (OCTA) image of the right eye of case 1 at baseline (a) and at 1-year follow-up (b).

a. OCTA image shows multiple, telangiectatic, microaneurysmal-like dilated vessels residing within the middle retinal layer and extending to the inner and outer retina in nasal juxtafoveal network. The vascular density of the temporal juxtafoveal network is less than the nasal juxtafoveal network. b. There seems to be a decrease in vessel density.

Case 2

A 78-year-old female presented with VA of 0.8 OD and 1.0 OS. Non-proliferative MacTel2 OD and proliferative MacTel2 OS were followed for 3 years. Intravitreal ranibizumab injection was applied 7 times due to foveal retinal hemorrhage OS. The VA of the patient was stable for 1 year and no additional treatment was given. The OCTA images of OS and image features are shown at baseline and 1-year follow-up (Figure 2a,b).

Case 3

A 56-year-old female presented with VA of 0.3 OD and 0.4 OS. The non-proliferative MacTel2 was present OU, was followed for 7 years and no treatment was performed. Six months after the first OCTA, VA of OD was 0.15. Fundus examination revealed foveal retinal hemorrhage OD. The OCT image of OD and image features are shown at 6 months (Figure 3b). Monthly intravitreal bevacizumab injections were applied to OD 5 times due to subretinal neovascularization (SRN). After 6 months, VA increased to 0.3 and retinal hemorrhage completely disappeared. The VA of OS was stable within 1 year. The OCTA images of OD and image features are shown at baseline and 1-year follow-up (Figure 3a,c).
Figure 2: Horizontal B-scan optical coherence tomography angiography (OCTA) image of the left eye of case 2 at baseline (a) and at 1-year follow-up (b). Both OCTA images show significant alterations in the temporal juxtafoveal network with prominent anastomoses. The presence of abnormal vessels corresponds to an area with retinal vascular anastomoses that extends to the outer retina where the ellipsoid zone is disrupted, forming a subretinal neovascularization.

Figure 3: Horizontal B-scan optical coherence tomography angiography (OCTA) and OCT images of the right eye of case 3 at baseline, 6-month and 1-year follow-up. 

a. Horizontal B-scan OCTA image at baseline. Although no findings were found in OCT, there is a prominent anastomoses in vascular the network between the outer retina and the choriocapillaris layers in the nasal juxtafoveal network in OCTA.

b. OCT image at 6-month follow-up. There are intraretinal hyporeflective cavitation, retinal pigment epithelium migration creating intraretinal hyperreflectivity, atrophy of the outer retinal layers, subretinal fluid, and subretinal neovascularization in the fovea.

c. Horizontal B-scan OCTA image at 1-year follow-up.
Discussion

The MacTel2 is a neurodegenerative and vascular disease limited to the macular area. Dysfunction and loss of Muller cells play an important role [6]. Loss of regulation of these cells may lead to photoreceptor death, dysregulation of angiogenic factors, vascular ectasia, and subsequent SRN [7].

OCTA has been recently used to analyze the macular capillary network in this disease [8]. OCTA has shown an increase in the intervascular spaces with progressive capillary rarefaction and abnormal capillary anastomosis and a vascular invasion in the normally avascular outer retina [9], [10]. Early changes in the retinal microvasculature begin temporal to the fovea in the DCP and then extend into the SCP [7], [8], [9], [10], [11]. OCTA imaging not only helps to facilitate the early diagnosis of MacTel2 but also provides a better understanding of disease progression and treatment efficacy [12].

This case series presents OCTA imaging features of nonproliferative and proliferative MacTel2 at 1-year follow-up. Proliferative and non-proliferative MacTel2 eyes showed marked reduction of VD of SCP and DCP at 1-year follow-up. The decrease in VD of DCP was greater than of SCP. For this reason, we think that ischemia may play a very important role in the pathogenesis and progression of MacTel2. We think that retinal atrophy and SRN may develop due to ischemia.

We did not use anti-vascular endothelial growth factor (VEGF) therapy because there was no decrease in VA of the patients with proliferative MacTel2 within 1 year, despite the detection of SRN in OCTA. One eye progressed to proliferative MacTel2 within 1 year. Although no findings were found in OCT, there was a prominent anastomosis in the vascular network between the outer retina and the choriocapillaris layers in OCTA at baseline. The VA decreased after 6 months. Despite anti-VEGF treatment, there is still SRN with high vascular density in OCTA. Therefore, if there is no decrease in VA, we think that anti-VEGF therapy is not necessary, even if the SRN is present in the OCTA, because it can increase retinal atrophy [13].

Conclusions

Based on the presented cases, the VD of MacTel2 patients might be decreased over time, more pronounced in the DCP. The VD of SCP and DCP may be an important parameter in long-term follow-up of MacTel2 patients. OCTA imaging provides a better understanding of disease progression. However, the presence of SRN with high VD in OCTA does not indicate that anti-VEGF therapy is required. Future studies with OCTA will hopefully illuminate additional features of MacTel2 and provide help in assessing treatment outcomes.

Notes

Competing interests

The authors declare that they have no competing interests.

References

1. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP. Macular telangiectasia type 2. Prog Retin Eye Res. 2013 May;34/49-77. DOI: 10.1016/j.preteyeres.2012.11.002
2. Runkle AP, Kaiser PK, Srivastava SK, Schachat AP, Reese JL, Ehlers JP. OCT Angiography and Ellipsoid Zone Mapping of Macular Telangiectasia Type 2 From the AVATAR Study. Invest Ophthalmol Vis Sci. 2017 Jul 158(9):3683-9. DOI: 10.1167/iovs.16-20976
3. Spaide RF, Klancnik JM Jr, Cooney MJ. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography. JAMA Ophthalmol. 2015 Jan;133(1):86-73. DOI: 10.1001/jamaophthalmol.2014.3950
4. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Bodi B. Idiopathic macular telangiectasia. 2006. Retina. 2012 Feb;32 Suppl 1:450-60. DOI: 10.1016/j.archopht.124.4.450
5. Huang Y, Zhang Q, Thorell MR, An L, Durbin MK, Lin M, Sharma U, Gregori G, Rosenfeld PJ, Wang RK. Swept-source OCT angiography of the retina vasculature using intensity differentiation-based optical microangiography algorithms. Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):382-9. DOI: 10.3928/23258160-20140909-08
6. Powner MB, Gillies MC, Zhu M, Vekis K, Hunyor AP, Fruttiger M. Loss of Müller’s cells and photoreceptors in macular telangiectasia type 2. Ophthalmology. 2013 Nov;120(11):2344-52. doi: 10.1016/j.ophtha.2013.04.013
7. Shen W, Fruttiger M, Zhu L, Chung SH, Barnett NL, Kirk JK, Lee S, Coorey NJ, Killingsworth M, Sherman LS, Gillies MC. Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. JNeurosci. 2012 Nov 7;32(45):15715-27. DOI: 10.1523/JNEUROSCI.2841-12.2012
8. Thorell MR, Zhang Q, Huang Y, Lin M, Durbin MK, Lin M, Sharma U, Stetson PF, Gregori G, Wang RK, Rosenfeld PJ. Swept-source OCT angiography of macular telangiectasia type 2. Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):369-80. DOI: 10.3928/23258160-20140909-06
9. Gaudric A, Krivosic V, Tadayon R. Outer retina capillary invasion and ellipsoid zone loss in macular telangiectasia type 2 imaged by optical coherence tomography angiography. Retina. 2015 Nov;35(11):2300-6. DOI: 10.1097/IAE.0000000000000799
10. Chidambaram L, Gadde SG, Yadav NK, Jayadev C, Bhanushali D, Appaji AM, Akkali M, Khurana A, Shetty R. Characteristics and quantification of vascular changes in maculartelangiectasia type 2 on optical coherence tomographyangiography. Br J Ophthalmol. 2016 Nov;100(11):1482-8. DOI: 10.1136/bjophthalmol-2015-307941
11. Dogan B, Erol MK, Akidan M, Suren E, Akar Y. Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2. Int Ophthalmol. 2019 Jan 3. DOI: 10.1007/s10 792-018-01060-x
12. Kupitz EH, Heeren TF, Holz FG, Charbel Issa P. Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina. 2015 Dec;35(12):2619-26. DOI: 10.1097/IAE.0000000000000715
13. Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. Progression of Macular Atrophy in Patients with Neovascular Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy. Retina. 2016 Oct;36(10):1843-50. DOI: 10.1097/IAE.0000000000001059

Corresponding author:
Mehmet Egemen Karatas
Department of Ophthalmology, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey
egemenkaratas@gmail.com

Please cite as
Demir ST, Güven D, Karatas ME, Dirim AB, Sendül SY, Ustaoglu M. Evaluation of 1-year follow-up results of macular telangiectasia type 2 cases by optical coherence tomography angiography. GMS Ophthalmol Cases. 2019;9:Doc29.
DOI: 10.3205/oc000118, URN: urn:nbn:de:0183-oc0001184

This article is freely available from
https://www.egms.de/en/journals/oc/2019-9/oc000118.shtml

Published: 2019-08-20

Copyright
©2019 Demir et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.